Opening the book…
This section provides an overview of the BARDA contract with Moderna. The publicly available version(s) of the contract are scans of redacted pages in the contract obtained via Freedom of Information requests.
Section B.1 Brief Description of Supplies/Services describes the scope of the project.[1,page 4, extracted verbatim]
"The Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA) requires the contractor(s) to develop a mRNA vaccine to licensure for the prevention of COVID-19. The project will entail pre-clinical and Phase 2 and Phase 3 clinical studies sufficient to demonstrate the safety and efficacy of the proposed vaccine(s); CMC development, scale-up, scale-out and validation of manufacturing capacities, including bulk drug substance and fill and finished drug product, with a capacity of 100 million doses by 2021 and all program management and regulatory activities necessary to achieve FDA licensure of the vaccine. The project shall be accomplished on an accelerated timeline, with parallel activity WBS, aggressive manufacturing scale-up, risk management, and taking advantage of any regulatory flexibilities. Contract terms include a requirement for domestic production of vaccine and assurance of material sourcing for vaccine production during execution of the project."
There is a discussion in the project management section of this textbook chapter that addresses the considerations of "accelerated timeline, with parallel activity WBS, aggressive manufacturing scale-up, risk management, and taking advantage of any regulatory flexibilities."
CPFF Contract
Section B.3 states that it is a Cost-Plus-Fixed-Fee (CPFF) contract.[1,page 4]
In contracting with the United States government, the following information is useful to know (extracted verbatim from the Federal Acquisition Regulation (FAR) [3], edited as needed).
FAR 16.306 Cost-plus-fixed-fee contracts
- Description. A cost-plus-fixed-fee contract is a cost-reimbursement contract that provides for payment to the contractor of a negotiated fee that is fixed at the inception of the contract. The fixed fee does not vary with actual cost, but may be adjusted as a result of changes in the work to be performed under the contract. This contract type permits contracting for efforts that might otherwise present too great a risk to contractors, but it provides the contractor only a minimum incentive to control costs.
- Application.
- A cost-plus-fixed-fee contract is suitable for use when the conditions of 16.301-2 are present and, for example-
- The contract is for the performance of research or preliminary exploration or study, and the level of effort required is unknown; or
- The contract is for development and test, and using a cost-plus-incentive-fee contract is not practical.
- A cost-plus-fixed-fee contract normally should not be used in development of major systems (see part 34) once preliminary exploration, studies, and risk reduction have indicated a high degree of probability that the development is achievable and the Government has established reasonably firm performance objectives and schedules.
- A cost-plus-fixed-fee contract is suitable for use when the conditions of 16.301-2 are present and, for example-
- Limitations. No cost-plus-fixed-fee contract shall be awarded unless the contracting officer complies with all limitations in 15.404-4(c)(4)(i) and 16.301-3.
- Completion and term forms. A cost-plus-fixed-fee contract may take one of two basic forms-completion or term.
- The completion form describes the scope of work by stating a definite goal or target and specifying an end product. This form of contract normally requires the contractor to complete and deliver the specified end product (e.g.,a final report of research accomplishing the goal or target) within the estimated cost, if possible, as a condition for payment of the entire fixed fee. However, in the event the work cannot be completed within the estimated cost, the Government may require more effort without increase in fee, provided the Government increases the estimated cost.
- The term form describes the scope of work in general terms and obligates the contractor to devote a specified level of effort for a stated time period. Under this form, if the performance is considered satisfactory by the Government, the fixed fee is payable at the expiration of the agreed-upon period, upon contractor statement that the level of effort specified in the contract has been expended in performing the contract work. Renewal for further periods of performance is a new acquisition that involves new cost and fee arrangements.
- Because of the differences in obligation assumed by the contractor, the completion form is preferred over the term form whenever the work, or specific milestones for the work, can be defined well enough to permit development of estimates within which the contractor can be expected to complete the work.
- The term form shall not be used unless the contractor is obligated by the contract to provide a specific level of effort within a definite time period.
Contract Periods
The contract defines several periods, where CLIN stands for Contract Line Item Number:
- Base period
- CLIN 0001: pre-award cost
- CLIN 0002: development of the mRNA vaccine to BLA
- Option period CLIN 0003: Domestic Manufacturing Scale-out
The total contract value for the above items is $483,298,520.00.
Moderna Contract Deliverables/WBS
| WBS item | Item Description | Deliverable |
|---|---|---|
| 1 | mRNA Vaccine Development | |
| 1.1 | Program Management | |
| 1.1.1 | Program and Alliance Management |
|
| 1.2 | Nonclinical Toxicology | |
| 1.2.2 | Safety | |
| 1.2.2.1 | Development and Reproductive Toxicology |
|
| 1.3 | Nonclinical | |
| 1.3.1 | Model Development (reserved) | |
| 1.3.1.2 | NHP Efficacy Study |
|
| 1.3.1.3 | Mouse Efficacy Study |
|
| 1.4 | Clinical | |
| 1.4.2 | Phase 2 | |
| 1.4.2.1 | Phase 2 Safety and lmmunogenicity Study |
|
| 1.4.3 | Phase 3 | |
| 1.4.3.1 | Phase 3 Efficacy or Safety and Imrnunogenicity |
|
| 1.4.3.2 | Phase 3 Lot-to-Lot |
|
| 1.4.3.3 | Phase 3 Adolescents |
|
| 1.5 | Regulatory | |
| 1.5.1 | IND | |
| 1.5.1.1 | IND Filing |
|
| 1.5.1.2 | IND Maintenance |
|
| 1.5.2 | BLA | |
| 1.5.1.1 | BLA Submission |
|
| 1.6 CMC | ||
| 1.6.3 | Pilot Scale Manufacturing | |
| 1.6.3.2 | CTM Manufacture for P201 |
|
| 1.6.3.4 | CTM Manufacture for P301 |
|
| 1.6.3.6 | CTM Manufacture for P302/P303 |
|
Section C.2 Statement of Work[1] lists WBS elements as well, and is covered in the Project Management Considerations section of this textbook.
Intellectual Property
Who owns the intellectual property produced under the contract? Is there a section of the contract that addresses this? Let's investigate this.
Section B.4.6 only addresses Facility, Equipment, and Product (e.g., vaccines, validated lots) ownership.
It might be addressed under Section B.4.13 Limited Rights Data, but the types of information covered are all redacted.[1, page 8]
Section 1 Intellectual Property [1, page 15] states (included verbatim): "The parties agree that that data generated prior to entering into or outside the scope of the agreement will, when delivered to the USG, be considered to be limited rights data subject to restrictions covered under FAR Clause 52.227-14 Alt II paragraph(g)(3). The government will obtain unlimited rights to data funded under this contract pursuant tp FAR Clause 52.227-14. The parties rights to subject inventions developed during performance of this contract will be governed by the terms of FAR Clause 52.227-11."
Federal Acquisition Regulation (FAR) Clause 52.227-11 [4] rendered for accessibility
52.227-11 Patent Rights-Ownership by the Contractor.
Patent Rights-Ownership by the Contractor (May 2014)
- As used in this clause-
Invention means any invention or discovery that is or may be patentable or otherwise protectable under title 35 of the U.S. Code, or any variety of plant that is or may be protectable under the Plant Variety Protection Act ( 7 U.S.C. 2321, et seq.)
Made means-
- When used in relation to any invention other than a plant variety, the conception or first actual reduction to practice of the invention; or
- When used in relation to a plant variety, that the Contractor has at least tentatively determined that the variety has been reproduced with recognized characteristics.
Nonprofit organization means a university or other institution of higher education or an organization of the type described in section 501(c)(3) of the Internal Revenue Code of 1954 ( 26 U.S.C. 501(c)) and exempt from taxation under section 501(a) of the Internal Revenue Code ( 26 U.S.C. 501(a)), or any nonprofit scientific or educational organization qualified under a State nonprofit organization statute.
"Practical application" means to manufacture, in the case of a composition of product; to practice, in the case of a process or method; or to operate, in the case of a machine or system; and, in each case, under such conditions as to establish that the invention is being utilized and that its benefits are, to the extent permitted by law or Government regulations, available to the public on reasonable terms.
Subject invention means any invention of the Contractor made in the performance of work under this contract.
- Contractor’s rights.
- Ownership. The Contractor may retain ownership of each subject invention throughout the world in accordance with the provisions of this clause.
- License.
- The Contractor shall retain a nonexclusive royalty-free license throughout the world in each subject invention to which the Government obtains title, unless the Contractor fails to disclose the invention within the times specified in paragraph (c) of this clause. The Contractor’s license extends to any domestic subsidiaries and affiliates within the corporate structure of which the Contractor is a part, and includes the right to grant sublicenses to the extent the Contractor was legally obligated to do so at contract award. The license is transferable only with the written approval of the agency, except when transferred to the successor of that part of the Contractor’s business to which the invention pertains.
- The Contractor’s license may be revoked or modified by the agency to the extent necessary to achieve expeditious practical application of the subject invention in a particular country in accordance with the procedures in FAR 27.302(i)(2) and 27.304-1(f).
- Contractor’s obligations.
- The Contractor shall disclose in writing each subject invention to the Contracting Officer within 2 months after the inventor discloses it in writing to Contractor personnel responsible for patent matters. The disclosure shall identify the inventor(s) and this contract under which the subject invention was made. It shall be sufficiently complete in technical detail to convey a clear understanding of the subject invention. The disclosure shall also identify any publication, on sale (i.e., sale or offer for sale), or public use of the subject invention, or whether a manuscript describing the subject invention has been submitted for publication and, if so, whether it has been accepted for publication. In addition, after disclosure to the agency, the Contractor shall promptly notify the Contracting Officer of the acceptance of any manuscript describing the subject invention for publication and any on sale or public use.
- The Contractor shall elect in writing whether or not to retain ownership of any subject invention by notifying the Contracting Officer within 2 years of disclosure to the agency. However, in any case where publication, on sale, or public use has initiated the 1-year statutory period during which valid patent protection can be obtained in the United States, the period for election of title may be shortened by the agency to a date that is no more than 60 days prior to the end of the statutory period.
- The Contractor shall file either a provisional or a nonprovisional patent application or a Plant Variety Protection Application on an elected subject invention within 1 year after election. However, in any case where a publication, on sale, or public use has initiated the 1-year statutory period during which valid patent protection can be obtained in the United States, the Contractor shall file the application prior to the end of that statutory period. If the Contractor files a provisional application, it shall file a nonprovisional application within 10 months of the filing of the provisional application. The Contractor shall file patent applications in additional countries or international patent offices within either 10 months of the first filed patent application (whether provisional or nonprovisional) or 6 months from the date permission is granted by the Commissioner of Patents to file foreign patent applications where such filing has been prohibited by a Secrecy Order.
- The Contractor may request extensions of time for disclosure, election, or filing under paragraphs (c)(1), (c)(2), and (c)(3) of this clause.
- Government’s rights-
- Ownership. The Contractor shall assign to the agency, on written request, title to any subject invention-
- If the Contractor fails to disclose or elect ownership to the subject invention within the times specified in paragraph (c) of this clause, or elects not to retain ownership; provided, that the agency may request title only within 60 days after learning of the Contractor's failure to disclose or elect within the specified times.
- In those countries in which the Contractor fails to file patent applications within the times specified in paragraph (c) of this clause; provided, however, that if the Contractor has filed a patent application in a country after the times specified in paragraph (c) of this clause, but prior to its receipt of the written request of the agency, the Contractor shall continue to retain ownership in that country.
- In any country in which the Contractor decides not to continue the prosecution of any application for, to pay the maintenance fees on, or defend in reexamination or opposition proceeding on, a patent on a subject invention.
- License. If the Contractor retains ownership of any subject invention, the Government shall have a nonexclusive, nontransferable, irrevocable, paid-up license to practice, or have practiced for or on its behalf, the subject invention throughout the world.
- Contractor action to protect the Government’s interest.
- The Contractor shall execute or have executed and promptly deliver to the agency all instruments necessary to-
- Establish or confirm the rights the Government has throughout the world in those subject inventions in which the Contractor elects to retain ownership; and
- Assign title to the agency when requested under paragraph (d) of this clause and to enable the Government to obtain patent protection and plant variety protection for that subject invention in any country.
- The Contractor shall require, by written agreement, its employees, other than clerical and nontechnical employees, to disclose promptly in writing to personnel identified as responsible for the administration of patent matters and in the Contractor's format, each subject invention in order that the Contractor can comply with the disclosure provisions of paragraph (c) of this clause, and to execute all papers necessary to file patent applications on subject inventions and to establish the Government's rights in the subject inventions. The disclosure format should require, as a minimum, the information required by paragraph (c)(1) of this clause. The Contractor shall instruct such employees, through employee agreements or other suitable educational programs, as to the importance of reporting inventions in sufficient time to permit the filing of patent applications prior to U.S. or foreign statutory bars.
- The Contractor shall notify the Contracting Officer of any decisions not to file a nonprovisional patent application, continue the prosecution of a patent application, pay maintenance fees, or defend in a reexamination or opposition proceeding on a patent, in any country, not less than 30 days before the expiration of the response or filing period required by the relevant patent office.
- The Contractor shall include, within the specification of any United States nonprovisional patent or plant variety protection application and any patent or plant variety protection certificate issuing thereon covering a subject invention, the following statement, "This invention was made with Government support under (identify the contract) awarded by (identify the agency). The Government has certain rights in the invention."
- Reporting on utilization of subject inventions. The Contractor shall submit, on request, periodic reports no more frequently than annually on the utilization of a subject invention or on efforts at obtaining utilization of the subject invention that are being made by the Contractor or its licensees or assignees. The reports shall include information regarding the status of development, date of first commercial sale or use, gross royalties received by the Contractor, and other data and information as the agency may reasonably specify. The Contractor also shall provide additional reports as may be requested by the agency in connection with any march-in proceeding undertaken by the agency in accordance with paragraph (h) of this clause. The Contractor also shall mark any utilization report as confidential/proprietary to help prevent inadvertent release outside the Government. As required by 35 U.S.C. 202(c)(5), the agency will not disclose that information to persons outside the Government without the Contractor’s permission.
- Preference for United States industry. Notwithstanding any other provision of this clause, neither the Contractor nor any assignee shall grant to any person the exclusive right to use or sell any subject invention in the United States unless the person agrees that any products embodying the subject invention or produced through the use of the subject invention will be manufactured substantially in the United States. However, in individual cases, the requirement for an agreement may be waived by the agency upon a showing by the Contractor or its assignee that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States, or that under the circumstances domestic manufacture is not commercially feasible.
- March-in rights. The Contractor acknowledges that, with respect to any subject invention in which it has retained ownership, the agency has the right to require licensing pursuant to 35 U.S.C. 203 and 210(c), and in accordance with the procedures in 37 CFR 401.6 and any supplemental regulations of the agency in effect on the date of contract award.
- Special provisions for contracts with nonprofit organizations. If the Contractor is a nonprofit organization, it shall-
- Not assign rights to a subject invention in the United States without the written approval of the agency, except where an assignment is made to an organization that has as one of its primary functions the management of inventions, provided, that the assignee shall be subject to the same provisions as the Contractor;
- Share royalties collected on a subject invention with the inventor, including Federal employee co-inventors (but through their agency if the agency deems it appropriate) when the subject invention is assigned in accordance with 35 U.S.C. 202(e) and 37 CFR 401.10;
- Use the balance of any royalties or income earned by the Contractor with respect to subject inventions, after payment of expenses (including payments to inventors) incidental to the administration of subject inventions for the support of scientific research or education; and
- Make efforts that are reasonable under the circumstances to attract licensees of subject inventions that are small business concerns, and give a preference to a small business concern when licensing a subject invention if the Contractor determines that the small business concern has a plan or proposal for marketing the invention which, if executed, is equally as likely to bring the invention to practical application as any plans or proposals from applicants that are not small business concerns; provided, that the Contractor is also satisfied that the small business concern has the capability and resources to carry out its plan or proposal. The decision whether to give a preference in any specific case will be at the discretion of the Contractor.
- Allow the Secretary of Commerce to review the Contractor’s licensing program and decisions regarding small business applicants, and negotiate changes to its licensing policies, procedures, or practices with the Secretary of Commerce when the Secretary’s review discloses that the Contractor could take reasonable steps to more effectively implement the requirements of paragraph (i)(4) of this clause.
- Communications. [Complete according to agency instructions.]
- Subcontracts.
- The Contractor shall include the substance of this clause, including this paragraph (k), in all subcontracts for experimental, developmental, or research work to be performed by a small business concern or nonprofit organization.
- The Contractor shall include in all other subcontracts for experimental, developmental, or research work the substance of the patent rights clause required by FAR subpart 27.3.
- At all tiers, the patent rights clause must be modified to identify the parties as follows: references to the Government are not changed, and the subcontractor has all rights and obligations of the Contractor in the clause. The Contractor shall not, as part of the consideration for awarding the subcontract, obtain rights in the subcontractor’s subject inventions.
- In subcontracts, at any tier, the agency, the subcontractor, and the Contractor agree that the mutual obligations of the parties created by this clause constitute a contract between the subcontractor and the agency with respect to the matters covered by the clause; provided, however, that nothing in this paragraph is intended to confer any jurisdiction under the Contract Disputes statute in connection with proceedings under paragraph (h) of this clause.
(End of clause)
Alternate I (Jun 1989). As prescribed in 27.303 (b)(3), add the following sentence at the end of paragraph (d)(2) of the basic clause:
The license shall include the right of the Government to sublicense foreign governments, their nationals and international organizations pursuant to the following treaties or international agreements: _______*
[*Contracting Officer complete with the names of applicable existing treaties or international agreements. The above language is not intended to apply to treaties or agreements that are in effect on the date of the award but are not listed.]
Alternate II (Dec 2007). As prescribed in 27.303 (b)(4), add the following sentence at the end of paragraph (d)(2) of the basic clause:
The agency reserves the right to unilaterally amend this contract to identify specific treaties or international agreements entered into by the Government before or after the effective date of the contract and effectuate those license or other rights that are necessary for the Government to meet its obligations to foreign governments, their nationals, and international organizations under the treaties or international agreements with respect to subject inventions made after the date of the amendment.
Alternate III (Jun 1989). As prescribed in 27.303 (b)(5), substitute the following paragraph (i)(3) in place of paragraph (i)(3) of the basic clause:
- After payment of patenting costs, licensing costs, payments to inventors, and other expenses incidental to the administration of subject inventions, the balance of any royalties or income earned and retained by the Contractor during any fiscal year on subject inventions under this or any successor contract containing the same requirement, up to any amount equal to 5 percent of the budget of the facility for that fiscal year, shall be used by the Contractor for the scientific research, development, and education consistent with the research and development mission and objectives of the facility, including activities that increase the licensing potential of other inventions of the facility. If the balance exceeds 5 percent, 75 percent of the excess above 5 percent shall be paid by the Contractor to the Treasury of the United States and the remaining 25 percent shall be used by the Contractor only for the same purposes as described above. To the extent it provides the most effective technology transfer, the licensing of subject inventions shall be administered by Contractor employees on location at the facility.
Alternate IV (Jun 1989). As prescribed in 27.303 (b)(6), include the following paragraph (e)(5) in paragraph (e) of the basic clause:
- The Contractor shall establish and maintain active and effective procedures to ensure that subject inventions are promptly identified and timely disclosed, and shall submit a description of the procedures to the Contracting Officer so that the Contracting Officer may evaluate and determine their effectiveness.
Alternate V (Dec 2007). As prescribed in 27.303 (b)(7), include the following paragraph (d)(3) in paragraph (d) of the basic clause:
(d)(3) CRADA licensing. If the Contractor performs services at a Government owned and operated laboratory or at a Government owned and Contractor operated laboratory directed by the Government to fulfill the Government’s obligations under a Cooperative Research and Development Agreement (CRADA) authorized by 15 U.S.C. 3710a, the Government may require the Contractor to negotiate an agreement with the CRADA collaborating party or parties regarding the allocation of rights to any subject invention the Contractor makes, solely or jointly, under the CRADA. The agreement shall be negotiated prior to the Contractor undertaking the CRADA work or, with the permission of the Government, upon the identification of a subject invention. In the absence of such an agreement, the Contractor agrees to grant the collaborating party or parties an option for a license in its inventions of the same scope and terms set forth in the CRADA for inventions made by the Government.
Use of Earned Value Management
Section B.4.3 Earned Value Management (EVM) Lite Requirements states: "The contractor shall use an Earned Value Management (EVM) System for all retrofit and development activities of the anticipate requirement, that is consistent with the '7 Principles of Earned Value Management, Tier 2 System Implementation Intent Guide' attached to this contract. Alternative systems may be submitted to the Contracting Officer for consideration and approval." [1, page 6]
Attachment 11 [1, page 83ff] is entitled "7 Principles of Earned Value Management, Tier 2 System Implementation Intent Guide." December 21, 2011. Its origins are the Department of Health & Human Services HHS Office of the Assistant Secretary for Preparedness ASPR, Biomedical Advanced Research and Development Authority BARDA.
BARDA's plan to implement Earned Value Management (for project management) is for three tiers, and tier 2 would apply to the BARDA vaccine work. Tier 2 is for countermeasure R&D work contracts that have total acquisition costs greater than or equal to $25 million and have a Technical Readiness Level (TRL) of less than 7. Those contracts will apply EVM principles for tracking cost, schedule and technical performance that comply with the 7 Principles of EVM Implementation (extracted verbatim below):
- Plan all work scope to completion.
- Break down the program work scope into finite pieces that can be assigned to a responsible person or organization for control of tech ical, schedule and cost objectives.
- Integrate program work scope, schedule, and cost objectives into a performance measurement baseline plan against which accomplishments can be measured. Control changes to the baseline.
- Use actual costs incurred and recorded in accomplishing the work performed.
- Objectively assess accomplishments at the work performance level.
- Analyze significant variances from the plan, forecast impacts, and pepare an estimate at completion based on performance to date and work to be performed.
- Use earned value information in the company's management processes.
References
- HHS-BARDA-Moderna-Contract-75A50120C00034-16April2020-Version8Feb2021. April 16, 2020. (Less redacted version obtained via FOIA lawsuit on February 8, 2021). BARDA Moderna contract. Note: Converted numbering to use formal numbered list or lettered lists for accessibility reasons.
- Transparency International Global Health. COVID-19 contracts. This site has links to COVID-19 contracts by country.
- Cost-plus-fixed-fee contracts. Information pulled January 4, 2026. Section 16.306 is about Cost-plus-fixed-fee contracts. FAR is "Federal Acquisition Regulation."
- Patent Rights Ownership by Contractor. Accessed January 4, 2026.
2.15.2.3: BARDA contract with Moderna is shared under a CC BY 4.0 license and was authored, remixed, and/or curated by LibreTexts.
The book could not be loaded just now.